Eshelman Ventures

Developing therapies for rare diseases, including Epidermolysis Bullosa (EB).

#Biotechnology / Rare disease therapeutics

Developing first-in-class RSK kinase inhibitors as targeted cancer therapies.

#Biotechnology / Oncology

Works with governments and partners to improve access to medicines in Sub-Saharan Africa across development, manufacturing, supply chains and patient delivery.

#Global health / Access to medicines

Pioneering a class of peptide antagonists; has clinical compounds ST101 (CEBP beta inhibitor for GBM) and ST316 (beta catenin inhibitor for colorectal cancer).

#Biotechnology / Oncology

In-licenses drug candidates and develops them through late-stage for sale to commercial companies.

#Private equity / Biopharma development

Developing cell-free biologics (exosomes) to treat neurodegenerative disorders and platforms to optimize delivery of RNAs, antibodies, genes and small molecules.

#Biotechnology / Biologics delivery

Developing on-demand pharmaceuticals to restore voluntary control of bladder and bowel for people with spinal cord injury and neurological conditions.

#Biotechnology / Neurological therapeutics

Provides 3D printing technology and services to accelerate product development and time-to-market.

#3D printing / Advanced manufacturing